$KRYS

Investing.com reported major US insider trades disclosed Friday. Buys: PAL director Rohit Lal bought $272.5k; OTLK director/10% owner Ghiath Sukhtian bought about 2.5M shares and warrants for ~$2.5M; CLPR director Sam Levinson bought ~$488.8k; OPFI CEO Todd Schwartz bought ~$144k; OPEN CEO Kasra Nejatian bought ~$100k. Sells: CRWV 10% owner Magnetar sold ~$231.6M then ~$213.8M; ANET CEO Ullal trust sales ~$119.3M; SEPN RA Capital sold $63.45M; KRYS director Rossi sold ~$8.23M.

Krystal Biotech director Dino A. Rossi sold about 25,000 shares for roughly $8.23m on Aug. 14, 2026, per an SEC Form 4, at weighted average prices of $325.60 to $333.23. He also gifted 3,691 shares to a donor-advised fund. Krystal Biotech reported Q2 diluted EPS of $1.79 (vs $1.70 est.) and revenue of $119.2m (vs $122.3m est.).

ROSSI DINO A sold 25,000 shares of Krystal Biotech, Inc. (KRYS) at an average of $329.12 ($325.60–$333.23, $8.23M total) across 8 trades on 2026-08-14.

Analyst notes on Friday included KeyBanc reiterating Apple as underweight, citing iPhone 17 carrier survey data slightly positive but with iPhone 18 price uncertainty. Bernstein upgraded Wayfair to Outperform, raising its PT to $125. Morgan Stanley reiterated Nvidia as overweight. Other calls covered Fox, Intuitive Machines, Cinemark, SanDisk, Energy Fuels, Digital Realty, SpaceX, Dell, Micron, and T-Mobile.

The article reports Friday’s Wall Street analyst research calls after cooler-than-expected CPI and PPI helped lift the S&P 500 to a record and Nasdaq up 0.81%. It cites upgrades, downgrades, and initiations including JPMorgan upgrading FoxA to Overweight with an $82 target and RBC initiating Krystal Biotech (KRYS) at $400. It also lists multiple other price targets across stocks.

Eli Lilly (LLY) reported Q2 results that beat forecasts and raised 2026 GAAP revenue guidance to $85B-$87B. Q2 revenue rose 48% to $22.974B and net income rose 25% to $7.095B. Leerink raised its 12-month price target to $1,309. Krystal Biotech (KRYS) shares fell after a slight Vyjuvek revenue miss, though analysts cited strong patient growth.

Simply Wall St reports Krystal Biotech (KRYS) Q2 2026 results: net income rose to $54.77M from $38.33M, with basic EPS from continuing ops at $1.85 and diluted EPS at $1.79. First-half 2026 net income was $110.70M. The piece links profitability to VYJUVEK demand and concentration risk.

Stocks settled sharply higher as Middle East tensions eased. The article cites a 66% chance of a +25 bp FOMC hike (Sept 15-16) and an 88% chance of an ECB +25 bp hike (Sept 10). WTI fell over 5%, lifting 10-year Treasuries and lowering yields. It also lists major movers including META (+6%), ORCL (+9%), and ATKR (+28%) after a $3.8B deal.

Markets were mixed as investors priced a 63% chance of a 25 bp FOMC hike on Sept. 15-16. U.S. 10-year yields fell to 4.688% and German bunds and UK gilts moved lower. Airline and cruise stocks rose as WTI dropped over 6%. Software gained, while semiconductors and energy fell. Notable movers included ATKR (+28%) on a $3.8B Prysmian deal and CNH (+16%) raising EPS guidance.

Markets rose as investors priced in easing geopolitical risks and US economic strength. The article cites a 63% chance of a +25 bp FOMC hike and notes US 10-year yields fell to 4.682%. It highlights stock moves including Meta (+5%), Amazon (+4%), and ATKR surging after Prysmian agreed to buy for $3.8B.